MCID: PNC006
MIFTS: 35

Pancreatic Somatostatinoma

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreatic Somatostatinoma

MalaCards integrated aliases for Pancreatic Somatostatinoma:

Name: Pancreatic Somatostatinoma 38 12 14 69
Pancreatic Delta Cell Somatostatin Producing Neoplasm 12
Pancreatic Somatostatin Cell Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4432
NCIt 47 C8006 C95595
UMLS 69 C1368041

Summaries for Pancreatic Somatostatinoma

MalaCards based summary : Pancreatic Somatostatinoma, also known as pancreatic delta cell somatostatin producing neoplasm, is related to wegmann jones smith syndrome and water-clear cell adenoma, and has symptoms including diarrhea An important gene associated with Pancreatic Somatostatinoma is SST (Somatostatin), and among its related pathways/superpathways is Neuroscience. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and pancreas.

Related Diseases for Pancreatic Somatostatinoma

Diseases related to Pancreatic Somatostatinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
id Related Disease Score Top Affiliating Genes
1 wegmann jones smith syndrome 10.5 CALCA SST
2 water-clear cell adenoma 10.5 CALCA SST
3 spinal muscular atrophy 10.5 CALCA SST
4 gastric gastrinoma 10.5 CALCA SST
5 mononeuritis of upper limb and mononeuritis multiplex 10.5 MEN1 SST
6 mental retardation, autosomal recessive 53 10.4 PPY SST
7 pancreatitis 10.4
8 somatostatinoma 10.4
9 mixed cell type adenoma of parathyroid 10.4 CALCA MEN1
10 strabismus 10.4 MEN1 SST
11 primary progressive multiple sclerosis 10.4 MEN1 SST
12 central hypoventilation syndrome, congenital 10.4 CALCA MEN1
13 lung giant cell carcinoma 10.4 MEN1 SST
14 breast apocrine carcinoma in situ 10.4 SST SYP
15 neuritis 10.4 SST SYP
16 worth's syndrome 10.4 CALCA SST
17 cardiovascular organ benign neoplasm 10.3 MEN1 SST
18 tamoxifen-related endometrial lesion 10.3 MEN1 PPY
19 neurogenic arthropathy 10.3 PPY SST
20 tabes dorsalis 10.3 SST SYP
21 rete ovarii cystadenofibroma 10.3 SST SYP
22 acquired aneurysmal subarachnoid hemorrhage 10.3 MEN1 SST
23 opioid abuse 10.3 CALCA MEN1
24 psychogenic movement 10.3 MEN1 SST
25 bladder cancer, childhood 10.3 SST SYP
26 parathyroid carcinoma 10.3 CALCA MEN1
27 chondroma 10.3 PPY SST
28 multiple endocrine neoplasia iib 10.3 CALCA MEN1
29 tricuspid valve insufficiency 10.3 CALCA SYP
30 uterine ligament clear cell adenocarcinoma 10.3 MEN1 SST
31 seminoma 10.3 SST SYP
32 sporadic hemiplegic migraine 10.2 CALCA MEN1
33 perianal skin paget's disease 10.2 PPY SYP
34 brain stem ependymoma 10.2 MEN1 SYP
35 endocervical adenocarcinoma 10.2 ENO2 SST
36 pituitary adenoma, acth-secreting 10.2 MEN1 SST
37 parathyroid oncocytic adenoma 10.2 CALCA MEN1
38 parietal lobe neoplasm 10.1 CALCA ENO2
39 hyperparathyroidism, familial primary 10.1 CALCA MEN1
40 usher syndrome, type 1f 10.1 MEN1 SST
41 optic papillitis 10.1 ENO2 SST
42 immunodeficiency, common variable, 5 10.0 MEN1 SST
43 tricuspid valve prolapse 10.0 CALCA ENO2
44 pandas 10.0 CALCA MEN1 SST
45 anal canal squamous cell carcinoma 10.0 CALCA ENO2
46 kartagener syndrome 10.0 CALCA MEN1 SST
47 cholelithiasis 10.0 ENO2 MEN1
48 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 10.0 CALCA MEN1 SST
49 2q31.1 microdeletion syndrome 10.0 ENO2 SYP
50 paranasal sinus cancer 10.0 ENO2 SYP

Graphical network of the top 20 diseases related to Pancreatic Somatostatinoma:



Diseases related to Pancreatic Somatostatinoma

Symptoms & Phenotypes for Pancreatic Somatostatinoma

UMLS symptoms related to Pancreatic Somatostatinoma:


diarrhea

Drugs & Therapeutics for Pancreatic Somatostatinoma

Drugs for Pancreatic Somatostatinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Antimetabolites Phase 2, Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
14 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
34
Pancrelipase Approved Phase 2 53608-75-6
35
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Streptozocin Approved Phase 2 18883-66-4 29327
38
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
39
Melphalan Approved Phase 2 148-82-3 4053 460612
40
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
41
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
42
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Anti-Bacterial Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 35)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
6 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
7 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
8 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
9 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
10 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
11 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
12 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
13 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
14 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
15 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
16 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
17 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
18 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
19 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
20 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
21 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
22 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
23 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
24 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
25 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
26 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
27 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
28 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
29 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
30 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
31 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
32 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
33 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
34 Ga-DOTATOC Versus Octreoscan + CT Suspended NCT01869725
35 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Pancreatic Somatostatinoma

Genetic Tests for Pancreatic Somatostatinoma

Anatomical Context for Pancreatic Somatostatinoma

MalaCards organs/tissues related to Pancreatic Somatostatinoma:

39
Liver, Pancreas, Bone, Kidney, Endothelial, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Somatostatinoma:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Delta Cells Affected by disease

Publications for Pancreatic Somatostatinoma

Articles related to Pancreatic Somatostatinoma:

(show all 30)
id Title Authors Year
1
Pancreatic somatostatinoma diagnosed preoperatively: report of a case. ( 24413789 )
2014
2
Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern. ( 20043348 )
2010
3
Cardiac metastasis from malignant pancreatic somatostatinoma. ( 19733881 )
2010
4
Pancreatic somatostatinoma characterized by extreme hypoglycemia. ( 19719976 )
2009
5
Pancreatic somatostatinoma with von Recklinghausen's disease. ( 18926936 )
2009
6
Pancreatic somatostatinoma manifested as severe hypoglycemia. ( 19565056 )
2009
7
FNAC diagnosis of pancreatic somatostatinoma. ( 21938182 )
2009
8
Pancreatic somatostatinoma and tuberous sclerosis: case report of an exceedingly rare association. ( 18672238 )
2009
9
Diagnosis and treatment of pancreatic somatostatinoma: a case report. ( 19080351 )
2008
10
Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. ( 16007666 )
2005
11
A small, incidentally detected pancreatic somatostatinoma: report of a case. ( 12560911 )
2003
12
Periampullary pancreatic somatostatinoma. ( 12417508 )
2002
13
Calcitonin-producing pancreatic somatostatinoma: report of a case. ( 9872549 )
1998
14
Reciprocal changes in progression of gastric mucosa-associated lymphoid tissue lymphoma and pancreatic somatostatinoma. ( 9870841 )
1998
15
Pancreatic somatostatinoma presenting with chronic intestinal pseudo-obstruction syndrome. ( 17912215 )
1996
16
Brain metastasis from malignant pancreatic somatostatinoma. Case report. ( 8814175 )
1996
17
Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. ( 7745981 )
1995
18
Pancreatic somatostatinoma: a case report and review of the literature. ( 1969977 )
1990
19
Pancreatic somatostatinoma. ( 2077482 )
1990
20
Malignant pancreatic somatostatinoma in a patient with dermatitis herpetiformis and coeliac disease. ( 2899527 )
1988
21
Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycaemia and ketoacidosis. ( 2855274 )
1988
22
Pancreatic somatostatinoma. ( 6314830 )
1983
23
Pancreatic somatostatinoma. ( 6314831 )
1983
24
Pancreatic somatostatinoma: abundance of somatostatin-28(1-12)-like immunoreactivity in tumor and plasma. ( 6137494 )
1983
25
Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma. ( 6105027 )
1980
26
Pancreatic somatostatinoma presenting with hypoglycaemia. ( 6105026 )
1980
27
Calcitonin-producing pancreatic somatostatinoma. ( 6102950 )
1980
28
Pancreatic somatostatinoma: histologic, clinical, and angiographic features. ( 227259 )
1979
29
Calcitonin secretion by a pancreatic somatostatinoma. ( 714084 )
1978
30
Pancreatic somatostatinoma. Clinical features and physiological implications. ( 66472 )
1977

Variations for Pancreatic Somatostatinoma

Expression for Pancreatic Somatostatinoma

Search GEO for disease gene expression data for Pancreatic Somatostatinoma.

Pathways for Pancreatic Somatostatinoma

Pathways related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.31 CALCA ENO2 SYP

GO Terms for Pancreatic Somatostatinoma

Cellular components related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 8.62 CALCA SYP

Biological processes related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 digestion GO:0007586 9.26 PPY SST
2 response to heat GO:0009408 9.16 CALCA SST
3 feeding behavior GO:0007631 8.96 CALCA PPY
4 cell-cell signaling GO:0007267 8.8 CALCA PPY SST

Molecular functions related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA PPY SST

Sources for Pancreatic Somatostatinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....